Erythromycin before endoscopy improves visualization of the gastric mucosa.

Published Date: 06 Mar 2023

A new study by Diego Adão and team has shown that using erythromycin before the exam can improve your ability to see your vision.

Read Full News

Latest News

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE Maria Abreu, MD

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

FDA Approves Bepirovirsen for Chronic Hepatitis B

ACG Annual Scientific Meeting 2026 Recap: 7 Trials to Know

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

News All Time

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Recommended News For You

Bayer is transforming pharmaceutical research into women's health

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds

SBRT May Beat Brachytherapy in Prostate Cancer

Recommended Articles For You

What Is Carboxyhemoglobin And How Can It Affect Your Health? 

Blood-Cell Morphology Foundation Models: Transforming Hematological Diagnostics and Clinical Practice 

Modern Updates in Hematology in the Digital Era 

Immune Niches Supporting Tumor Dormancy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

2.

Virtual Reality Travel Reduces Cancer Pain.

3.

Teclistamab Alone Ups Previously Treated Myeloma Survival

4.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

5.

Oleanolic acid from grapes may increase chemotherapy effectiveness

1.

Clinical Guidelines for Cancer-Associated Thrombosis Monitoring

2.

Altered Bone-Marrow Microenvironment Dynamics During Ineffective Hematopoiesis

3.

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment

4.

Treatment-Related Immune Dysfunction and Infection Risk in Cancer

5.

Managing Symptom Support During Cancer Treatment Transitions

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Clinical Insights in Oncology

2.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

4.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot